NAVELBINE 30 MG 1 CAP (XX)

Vinorelbine is a semisynthetic vinca alkaloid with antineoplastic activity similar to vinblastine. It is used, alone or with other antineoplastics, in the first-line treatment of non-small cell lung cancer and in the treatment of advanced breast cancer that has relapsed or is refractory to an anthracycline-containing regimen.

NAVELBINE (VINORELBINE) 30 mg, soft capsule. Oral Use.
Box of one 30 mg soft capsule

Therapeutic indications:
As a single agent or in combination for:
– The first line treatment of stage 3 or 4 non small cell lung cancer.
– The treatment of advanced breast cancer stage 3 and 4 relapsing after or refractory to an anthracycline containing regimen.

Pharmacotherapeutic group:
Vinca alkaloïds and analogues (ATC Code: L01C A04)

Mechanism of action:
Navelbine is a antineoplastic drug of the vinca alkaloid family but unlike all the other vinca alkaloids, the catharantine moiety of vinorelbine has been structurally modified. At the molecular level, it acts on the dynamic equilibrium of tubulin in the microtubular apparatus of the cell. It inhibits tubulin polymerization and binds preferentially to mitotic microtubules, affecting axonal microtubules at high concentrations only. The induction of tubulin spiralization is less than that produced by vincristine.
Navelbine blocks mitosis at G2-M, causing cell death in interphase or at the following mitosis.

Composition:
Vinorelbine tartrate 41.55 mg, corresponding to vinorelbine base 30.00 mg
Excipients qs one capsule.
Also includes Sorbitol.

Store between 2 degrees C and 8 degrees C (in a refrigerator).
Store in the original container.
Keep out of the reach and sight of children.

PIERRE FABRE ONCOLOGIE
Manufactured by: PIERRE FABRE MEDICAMENT PRODUCTION
استيراد الشركة المصرية لتجارة الأدوية
NAVELBINE: a registered trademark of PIERRE FABRE MEDICAMENT

PIERRE FABRE MEDICAMENT
45, place Abel-Gance
92100 Boulogne
France